|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:2783–2795. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Kang FB, Wang J, Yang C and He DW:
Downregulation of miR-205 contributes to epithelial-mesenchymal
transition and invasion in triple-negative breast cancer by
targeting HMGB1-RAGE signaling pathway. Anticancer Drugs.
30:225–232. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu F, Xing T, Gao X and Liu F: miR-501-3p
promotes colorectal cancer progression via activation of
Wnt/β-catenin signaling. Int J Oncol. 55:671–683. 2019.PubMed/NCBI
|
|
7
|
Yao L, Shi W and Gu J: Micro-RNA 205-5p is
involved in the progression of gastric cancer and targets
phosphatase and tensin homolog (PTEN) in SGC-7901 human gastric
cancer cells. Med Sci Monit. 25:6367–6377. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu A, Zhang Y, Zhao X, Li J and Ying Y:
CBX1 is a direct target of miR-205-5p and contributes to the
progression of pituitary tumor. Pharmazie. 74:154–156.
2019.PubMed/NCBI
|
|
9
|
Chen S, Jin L, Nie S, Han L, Lu N and Zhou
Y: miR-205 inhibits neuroblastoma growth by targeting
cAMP-responsive element-binding protein 1. Oncol Res. 26:445–455.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang X, Yang L, Ma Y, Zhao X and Wang H:
MicroRNA-205 mediates proteinase-activated receptor 2
(PAR2)-promoted cancer cell migration. Cancer Invest. 35:601–609.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pang H and Yue X: MiR-205 serves as a
prognostic factor and suppresses proliferation and invasion by
targeting insulin-like growth factor receptor 1 in human cervical
cancer. Tumour Biol. Jun 27–2017.(Epub ahead of print). doi
org/10.1177/1010428317701308. View Article : Google Scholar
|
|
12
|
Liu Y, Qian XM, He QC and Weng JK: MiR-421
inhibition protects H9c2 cells against
hypoxia/reoxygenation-induced oxidative stress and apoptosis by
targeting Sirt3. Perfusion. Aug 30–2019.(Epub ahead of print). doi:
10.1177/0267659119870725. View Article : Google Scholar
|
|
13
|
Mei JW, Yang ZY, Xiang HG, Bao R, Ye YY,
Ren T, Wang XF and Shu YJ: MicroRNA-1275 inhibits cell migration
and invasion in gastric cancer by regulating vimentin and
E-cadherin via JAZF1. BMC Cancer. 19:7402019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ye K, Xu C and Hui T: MiR-34b inhibits the
proliferation and promotes apoptosis in colon cancer cells by
targeting Wnt/β-catenin signaling pathway. Biosci Rep.
39:BSR201917992019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiao D, Guo F and Fu Q: MicroRNA 873
inhibits the progression of thyroid cancer by directly targeting
ZEB1. Mol Med Rep. 20:1986–1993. 2019.PubMed/NCBI
|
|
16
|
Guo H and Zhang L: MicroRNA-30a suppresses
papillary thyroid cancer cell proliferation, migration and invasion
by directly targeting E2F7. Exp Ther Med. 18:209–215.
2019.PubMed/NCBI
|
|
17
|
Dai B, Zhou G, Hu Z, Zhu G, Mao B, Su H
and Jia Q: MiR-205 suppresses epithelial-mesenchymal transition and
inhibits tumor growth of human glioma through downregulation of
HOXD9. Biosci Rep. 39:392019. View Article : Google Scholar
|
|
18
|
Zhuang L, Guo J, Yao Y and Li Z: miR-205
targets runt-related transcription factor 2 to inhibit human
pancreatic cancer progression. Oncol Lett. 17:843–848.
2019.PubMed/NCBI
|
|
19
|
Lu J, Lin Y, Li F, Ye H, Zhou R, Jin Y, Li
B, Xiong X and Cheng N: MiR-205 suppresses tumor growth, invasion,
and epithelial-mesenchymal transition by targeting SEMA4C in
hepatocellular carcinoma. FASEB J. May 25–2018.(Epub ahead of
print). doi: 10.1096/fj.201800113R. View Article : Google Scholar
|
|
20
|
Ballew O and Lacefield S: The DNA damage
checkpoint and the spindle position checkpoint: Guardians of
meiotic commitment. Curr Genet. 65:1135–1140. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hochegger H, Takeda S and Hunt T:
Cyclin-dependent kinases and cell-cycle transitions: Does one fit
all? Nat Rev Mol Cell Biol. 9:910–916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian X, Song X, He Y, Yang Z, Sun T, Wang
J, Zhu G, Xing W and You C: CCNB2 overexpression is a poor
prognostic biomarker in Chinese NSCLC patients. Biomed
Pharmacother. 74:222–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lei CY, Wang W, Zhu YT, Fang WY and Tan
WL: The decrease of cyclin B2 expression inhibits invasion and
metastasis of bladder cancer. Urol Oncol. 34:237.e1–237.e10. 2016.
View Article : Google Scholar
|
|
24
|
Shi Q, Wang W, Jia Z, Chen P, Ma K and
Zhou C: ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes,
promotes gastric cancer cell proliferation and tumor growth.
Oncotarget. 7:36489–36500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shubbar E, Kovács A, Hajizadeh S, Parris
TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K:
Elevated cyclin B2 expression in invasive breast carcinoma is
associated with unfavorable clinical outcome. BMC Cancer. 13:12013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li R, Jiang X, Zhang Y, Wang S, Chen X, Yu
X, Ma J and Huang X: Cyclin B2 overexpression in human
hepatocellular carcinoma is associated with poor prognosis. Arch
Med Res. 50:10–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
